Digital Health February 9, 2023
Cora Lydon

Macmillan Cancer Support has invested in Neutrocheck, a portable device and app being developed by 52 North Health, to help people with cancer test for neutropenic sepsis from their own homes.

Neutrocheck’s device is centred around an at-home finger prick test that could detect the life-threatening reaction to an infection. This could prove vital for patients undergoing chemotherapy who may be immune suppressed, making them more likely to develop neutropenic sepsis.

Currently, if they sent to A&E, they are given appropriate antibiotics as a precaution and undergo a full blood test.

With the test, patients can check their risk at home, allowing them to take informed and immediate steps to seek care and be prioritised at hospitals. It also helps...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Apps, Digital Health, Home, Investments, Patient / Consumer, Technology, Trends
Mass General Brigham, Best Buy advance hospital at home
‘Future Of Medicine’: SNF-at-Home Gains Traction as Alternative to Nursing Homes Amid Access Crisis
Hospital-At-Home Could Remain In Play With Continuing Resolution
How Stanford is doing home care differently
Another Reprieve? Proposed Budget Bill Includes Telehealth, HaH Extensions

Share This Article